NASHVILLE, Tenn. - HCA Healthcare, Inc. (NYSE: NYSE:HCA) has reported a robust second quarter with earnings and revenue exceeding analyst expectations, prompting the company to raise its full-year 2024 guidance.
The healthcare provider's stock surged 7% in premarket trading following the report.
For the second quarter ended June 30, 2024, HCA Healthcare announced revenues of $17.492 billion, a notable increase from $15.861 billion in the same quarter last year, representing a 10.3% rise. The company's adjusted earnings per share (EPS) stood at $5.53, surpassing the analyst estimate of $4.93. This performance reflects a significant improvement from the $4.29 EPS reported in the second quarter of 2023.
The company's CEO, Sam Hazen, attributed the positive results to strong demand for HCA Healthcare's services and the effective execution of their strategic plan. "Our teams continued to execute our strategic plan effectively and produce positive outcomes for our patients," Hazen said, acknowledging the efforts of HCA colleagues in driving the company's success.
Looking ahead, HCA Healthcare has raised its full-year 2024 EPS guidance to a range of $21.60 to $22.80, well above the consensus estimate of $20.98. Revenue projections for the year have also been increased to between $69.75 billion and $71.75 billion, closely aligning with the consensus estimate of $69.79 billion.
HCA Healthcare operates 188 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers, and physician clinics, across 20 states and the United Kingdom.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.